From: Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints
Learning Phase Paradigms | |
• Adaptive dose-finding for toxicity (Bayesian or Frequentist) | |
• Adaptive dose finding for efficacy (Bayesian or Frequentist) | |
• Seamless phase I/IIa | |
Confirmatory Phase Paradigms | |
• Group sequential | |
• Sample size re-estimation | |
• Adaptive randomization based on observed response | |
• Adaptive randomization based upon covariate | |
• Enrichment Designs | |
• Adaptive treatment-switching design | |
• Adaptive seamless phase II/III | |
Adaptive hypotheses | |
• Superiority to non-inferiority |